Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

Abroad (travel likely)Recruiting

Conditions

Brain Tumors · Medulloblastoma · Glioma · Ependymoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tata Memorial Hospital (TMH) Parel, and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Mumbai, Maharashtra, India
Contact: Study coordinator (Dr. Archya Dasgupta, MBBS, MD) · archya1010@gmail.com · 91-22-24177000

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Glioma · Medulloblastoma · Ependymoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Glioblastoma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma

Abroad (travel likely)RecruitingPHASE2

New York, United States

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Ependymoma · Medulloblastoma · Glioblastoma

Abroad (travel likely)RecruitingPHASE1

Augusta, United States

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Glioma · Glioneuronal Tumor · Choroid Plexus Tumor

Abroad (travel likely)Recruiting

Innsbruck, Austria · Vienna, Austria